Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C2H3Cl3O4P.Na |
| Molecular Weight | 251.365 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].OP([O-])(=O)OCC(Cl)(Cl)Cl
InChI
InChIKey=WFKJEZKHPGDCRK-UHFFFAOYSA-M
InChI=1S/C2H4Cl3O4P.Na/c3-2(4,5)1-9-10(6,7)8;/h1H2,(H2,6,7,8);/q;+1/p-1
| Molecular Formula | C2H3Cl3O4P |
| Molecular Weight | 228.376 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Triclofos is primarily indicated in conditions like Insomnia, and can also be given in adjunctive therapy as an alternative drug of choice in Nausea, vertigo, labyrinthine disorders. It is also used sedate people suffering from anxiety or tension before medical investigations. Triclofos is converted to Trichloroethanol in the body .This act on brain and produces sleep. Trichloroethanol decreases time taken to fall asleep and lengthen the sleep. Triclofos is most commonly used agent for sedation in
neonates as well as in older infants and children in Japan.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | TRICLOS Approved UseTriclofos is used to treat sleeping problems (insomnia) in people. It is also used sedate people suffering from anxiety or tension before medical investigations. |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8 h |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
TRICLOFOS plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
65% |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
TRICLOFOS plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Modeling hydroxyl radical distribution and trialkyl phosphates oxidation in UV-H2O2 photoreactors using computational fluid dynamics. | 2010-08-15 |
|
| Procedural sedation analgesia. | 2010-01 |
|
| Proteomic analysis of regenerating mouse liver following 50% partial hepatectomy. | 2009-12-29 |
|
| Comparison of solvent mixtures for pressurized solvent extraction of soil fatty acid biomarkers. | 2008-10-19 |
|
| Transient administration of triclofos sodium is helpful in minimizing anticonvulsants under polypharmacy. | 2006-12 |
|
| Efficacy and adverse effects of rectal thiamylal with oral triclofos for children undergoing magnetic resonance imaging. | 2006-04 |
|
| A method for screening for various sedative-hypnotics in serum by liquid chromatography/single quadrupole mass spectrometry. | 2006-02-10 |
|
| [Severe airway obstruction relieved by sedation using sevoflurane in a pediatric patient with tracheobronchomalacia]. | 2005-02 |
|
| An analysis of oxygen consumption and oxygen delivery in euthermic infants after cardiopulmonary bypass with modified ultrafiltration. | 2004-10 |
|
| Non-epileptic pedaling-like movement induced by triclofos. | 2004-10 |
|
| A pediatric sedation/anesthesia program with dedicated care by anesthesiologists and nurses for procedures outside the operating room. | 2004-07 |
|
| A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. | 2002 |
|
| Neonatal outcome following maternal opiate use in late pregnancy. | 2001-09 |
|
| Comparison of resistance measured by the interrupter technique and by passive mechanics in sedated infants. | 2001-08 |
|
| Iatrogenic encephalopathy. | 1970-05 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://en.pharmacodia.com/web/drug/1_9972.html
The usual adult dose as a hypnotic is 1 to 2 g orally at night. A suggested hypnotic dose for children 1 month to 1 year of age is 25 to 30 mg/kg; children aged 1 to 5 years may be given single doses of 250 to 500 mg, and children aged 6 to 12 years may be given single doses of 0.5 to 1 g.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:02:25 GMT 2025
by
admin
on
Mon Mar 31 18:02:25 GMT 2025
|
| Record UNII |
9F90KA5Q8U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29756
Created by
admin on Mon Mar 31 18:02:25 GMT 2025 , Edited by admin on Mon Mar 31 18:02:25 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB15606MIG
Created by
admin on Mon Mar 31 18:02:25 GMT 2025 , Edited by admin on Mon Mar 31 18:02:25 GMT 2025
|
PRIMARY | |||
|
DBSALT001424
Created by
admin on Mon Mar 31 18:02:25 GMT 2025 , Edited by admin on Mon Mar 31 18:02:25 GMT 2025
|
PRIMARY | |||
|
23677832
Created by
admin on Mon Mar 31 18:02:25 GMT 2025 , Edited by admin on Mon Mar 31 18:02:25 GMT 2025
|
PRIMARY | |||
|
m11090
Created by
admin on Mon Mar 31 18:02:25 GMT 2025 , Edited by admin on Mon Mar 31 18:02:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
230-652-3
Created by
admin on Mon Mar 31 18:02:25 GMT 2025 , Edited by admin on Mon Mar 31 18:02:25 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201317
Created by
admin on Mon Mar 31 18:02:25 GMT 2025 , Edited by admin on Mon Mar 31 18:02:25 GMT 2025
|
PRIMARY | |||
|
DTXSID60993262
Created by
admin on Mon Mar 31 18:02:25 GMT 2025 , Edited by admin on Mon Mar 31 18:02:25 GMT 2025
|
PRIMARY | |||
|
7246-20-0
Created by
admin on Mon Mar 31 18:02:25 GMT 2025 , Edited by admin on Mon Mar 31 18:02:25 GMT 2025
|
PRIMARY | |||
|
9F90KA5Q8U
Created by
admin on Mon Mar 31 18:02:25 GMT 2025 , Edited by admin on Mon Mar 31 18:02:25 GMT 2025
|
PRIMARY | |||
|
104696
Created by
admin on Mon Mar 31 18:02:25 GMT 2025 , Edited by admin on Mon Mar 31 18:02:25 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000077273
Created by
admin on Mon Mar 31 18:02:25 GMT 2025 , Edited by admin on Mon Mar 31 18:02:25 GMT 2025
|
PRIMARY | |||
|
C66630
Created by
admin on Mon Mar 31 18:02:25 GMT 2025 , Edited by admin on Mon Mar 31 18:02:25 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |